Macrophage Pharma is an immuno-oncology company focussed on the discovery and development of novel therapies designed to enhance anti-tumour immune responses.
Macrophage Pharma’s technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body’s natural immune system to fight cancer.
Macrophage Pharma’s novel Esterase Sensitive Motif™ (ESM™) technology has delivered agents which are being developed to induce targeted and durable anti-tumour immune responses and provide next-generation immunotherapy with broad utility in oncology.
Macrophage Pharma’s approach is to create a more hostile environment for tumour growth by:
- Reprogramming tumour macrophages to stimulate the anti-tumour immune response
- Reversing immunosuppression in the tumour microenvironment
- Converting tolerogenic dendritic cells to effective antigen presenting cells
The company is exploiting a unique and proprietary knowledge base to unleash the full therapeutic potential of ESM technology in immuno-oncology.
- Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference 7th November 2017
- Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures 23rd August 2017
- Macrophage Pharma Appoints Development Director 11th May 2017
- Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform 9th January 2017
Macrophage Pharma s primary goal is to develop a new generation of powerful small-molecule immuno-oncology drugs which inhibit the ability of tumour polarised macrophages to release immunosuppressive cytokines.
The foundation of Macrophage Pharma s approach is its proprietary Esterase Sensitive Motif (ESM™) technology. The technology involves the use of specifically designed amino acid ester motifs that are selectively hydrolysed.
R D PROJECTS
Macrophage Pharma s lead programme is focused on the novel macrophage targeted p38 MAPK inhibitor, CHR-6155, supported by a strong package of non-clinical immuno-oncology and early safety pharmacology data.
Copyright 2017 Macrophage Pharma. All rights reserved.